Showing 7931-7940 of 8465 results for "".
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- Investigational Foam May Offer Itch Relief for Psoriasis Patientshttps://practicaldermatology.com/news/investigational-foam-may-offer-itch-relief-for-psoriasis-patients/2458931/An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congress of Dermatology. According to the Phase 3 clinical trial, 426 psoriasis patients were split int
- ASDSA Supports FDA Fillers Directivehttps://practicaldermatology.com/news/asdsa-supports-fda-fillers-directive/2458935/A recent FDA directive that soft-tissue filler manufacturers include additional precautions on product labels underscores the importance of patients seeking expert physicians for their treatments, according to the American Society for Dermatologic Surgery Association (ASDSA). The FDA is a
- Chief Academy Convenes in San Antoniohttps://practicaldermatology.com/news/chief-academy-convenes-in-san-antonio/2458938/The 2015 Chief Academy convened this month on the campus of the University of Texas Health Science Center - San Antonio, marking a move for the meeting from its 7-year home in Chicago. Dr. Vineet Mishra, Director of Mohs Surgery and Procedural Dermatology as w
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Skin Cancer Screening Initiative from AAD: ‘Who's Got Your Back?'https://practicaldermatology.com/news/skin-cancer-screening-initiative-from-aad-whos-got-your-back/2458952/In recognition of Melanoma/Skin Cancer Detection and Prevention Month in May and Melanoma Monday, observed on May 4 this year, the American Academy of Dermatology (AAD) asks the public to consider “Who’s Got Your Back?” when it comes to applying sunscreen and examining skin for
- Galderma to Enter Nutraceutical Markethttps://practicaldermatology.com/news/galderma-to-enter-nutraceutical-market/2458954/Galderma entred into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity.
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N